Viking's obesity pill VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in body ...

Novo is far from the only big pharma company bolstering DTC medicine offerings. Novo’s main rival in the GLP-1RA arena, Eli ...

CSL’s headcount reduction and vaccine spinoff dragged shares down 9.5%, from A$271.32 at market close on 18 August to ...

Santen has signed an agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein for retinal ...

Every aspect of science and research is based on data, and across the globe, labs are producing more data than the average ...

Clinical supply chains are transforming, and so are the technological barriers to entry for firms in Life Sciences. To stay ...

Precigen’s immunotherapy will likely reduce the need for repeat surgeries in recurrent respiratory papillomatosis (RRP) ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

Aquestive has entered a strategic funding agreement worth $75m with RTW Investments, aimed at supporting the potential launch ...

Sanofi has received orphan designation from the EMA for rilzabrutinib, a reversible covalent BTK inhibitor, to treat IgG4-RD.

Clinical trial data management is growing increasingly complex, with inefficiencies driving up costs and delaying timelines.